Skip to main content

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH)

By: Newsfile

Dallas, Texas--(Newsfile Corp. - September 30, 2022) - Bio-Path Holdings, Inc. (Nasdaq: BPTH): The full report can be accessed by clicking on the following link:

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Bio-Path's pipeline continues to expand with new cancer indications
  • Bio-Pathhas completed Phase 1 clinical trials for its lead candidate prexigebersen for AML and other blood cancers
  • The Company most recently reported that cash on hand as of 6/30/22 is sufficient to fund operations according to plan for at the next 12 months

Cannot view this image? Visit:

Click image above to view full announcement.

About Stonegate Capital Partners
Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high-quality investment opportunities.


Stonegate Capital Partners
(214) 987-4121

Source: Stonegate, Inc.

To view the source version of this press release, please visit

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.